Abstract CT037: A first-in-human phase 1 trial of a novel claudin 6 (CLDN6)-targeting antibody drug conjugate (ADC) QLS5132 in patients (pts) with platinum-resistant ovarian cancer (PROC)

作者：X L Yang, Zhengbo Song, Juan Li, Liang Chen, Yang Sun, D Zou, Y Li, S H Zhang, Yan Ding, Yu Gu, Xin Liu, Tao Zhang, Xiaoyan Kang, Weikang Tao, Tao Zhu · 发表于：Cancer Research · 年份：2026 · DOI：10.1158/1538-7445.am2026-ct037 · 被引用次数：1 · 研究领域：Barrier Structure and Function Studies、Cell Adhesion Molecules Research、HER2/EGFR in Cancer Research

Abstract Background: QLS5132 is a highly selective ADC composed of a humanized anti-CLDN6 hIgG1 antibody and a novel topoisomerase-1 inhibitor as cytotoxic payload via a hydrophilic cleavable linker LK1b, with a drug-to-antibody ratio of 8. QLS5132 showed an expanded therapeutic window and potent antitumor activity in PROC in preclinical studies. Methods: The trial (NCT06932094) recruited pts with histologically or cytologically confirmed advanced PROC, who failed or had no standard therapy. Accelerated titration design and Bayesian optimal interval design were adopted in dose-escalation stage. QLS5132 was administered via intravenous infusion once Q3W at dose levels of 1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg, 5.6 mg/kg, and 6.4 mg/kg. Two dose levels would be selected in dose-expansion phase. The primary endpoints were safety. Results: As of Jan 21, 2026, 28 pts with advanced PROC were enrolled (ovarian cancers:26 pts, fallopian tube cancers:2 pts). The dose-escalation for the 6.4 mg/kg cohort was completed. Median age was 57.5 years. Ten (35.7%) pts received ≥5 lines of prior treatment, 25 (89.3%) pts received prior bevacizumab, and 22 (78.6%) pts received prior polyADP ribose polymerase inhibitors. Dose-limiting toxicity of grade 4 platelet count decreased occurred in one patient at 6.4 mg/kg dose level. Twenty-six (92.9%) pts experienced TEAEs (treatment-related, 92.9%). The most common TRAEs of any grade with incidence >50% were nausea (85.7%), anorexia (60.7%), anemia (5...